A Study of AL8326 in Non-Small Cell Lung Cancer

Phase 1

Active, not recruiting

• Conditions: Non-small Cell Lung Cancer
• Interventions: Drug: AL8326 tablets

• Registration Number: NCT06794957
• Lead Sponsor: Advenchen Laboratories, LLC

Brief Summary

This trial is a multicenter, single arm, open, phase IB clinical trial, designed to evaluate the preliminary efficacy and safety of AL8326 in patients with non-small cell lung cancer (NSCLC) who relapsed or progressed after multi line treatment and failed standard treatment.

Detailed Description

The subjects received the test drug al8326 tablets in the order of enrollment (oral administration, once a day, one cycle every 28 days) until intolerable toxicity or disease progression or death or voluntary withdrawal or the end of this study. The subjects will conduct anti-tumor efficacy evaluation and corresponding safety inspection every 2 cycles, and determine the tumor disease status according to the solid tumor efficacy evaluation criteria (RECIST 1.1).

Subjects requiring pharmacokinetic analysis will be randomly treated with trial drug AL8326 tablets 60mg QD or 40mg QD (oral administration, once a day, one cycle every 28 days) in a 1:1 ratio.

Study Timeline

• Study Start: 2022-05-19
• Study First Submitted: 2024-01-30
• Status Verified: 2024-02
• Study First Submitted QC: 2025-01-24
• Last Update Submitted: 2025-01-24
• Study First Posted: 2025-03-25
• Last Update Posted: 2025-03-25
• Primary Completion: 2027-12
• Study Completion: 2027-12

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 158

Inclusion Criteria

1. Subjects must be able to understand and be willing to sign a written informed consent form before beginning any study-related procedures;

2. Age ≥18 years, both male and female;

3. Patients with advanced non-small cell lung cancer who failed standard treatment confirmed by pathology (disease progression after treatment or intolerable toxic and side effects of treatment) or did not have standard treatment (group A: Patients with non-small cell lung cancer without brain metastasis confirmed by imaging at baseline; group B: Patients with non-small cell lung cancer with brain metastasis confirmed by imaging at baseline)；

4. Have received at least two or more systemic treatment regimens;

5. Have at least one measurable tumor lesion according to the criteria for evaluating the efficacy of solid tumors (RECIST 1.1);

6. Have received prior chemotherapy with a cytotoxic agent, with an interval of at least 4 weeks between the end of chemotherapy and the time of enrollment, and have recovered to grade ≤1 (except alopecia areata) from a toxic reaction to prior chemotherapy

7. Life expectancy ≥ 12 weeks.

8. Eastern Cooperative Oncology Group（ECOG） score of 0 -1.

9. Subjects have adequate organ and bone marrow function and meet the following laboratory test criteria:

   1. Bone marrow function: absolute neutrophil count (ANC) ≥ 1.5 x 10^9 /L (1500/mm^3), platelets ≥ 80 x 10^9/L;cifang
   2. Hemoglobin ≥ 9.0 g/dl;
   3. Liver function: serum total bilirubin ≤ 1.5 times the upper limit of normal (ULN), except for patients with Gilbert's syndrome (persistent or recurrent hyperbilirubinemia manifesting as elevated unconjugated bilirubin in the absence of evidence of hemolysis or hepatic pathology); and for those without liver transfer, alanine aminotransferase ( ALT ）and aspartate aminotransferase (AST) ≤ 2.5 × ULN for those without liver metastases, and ALT and AST ≤ 5 × ULN for those with liver metastases;
   4. Renal function: serum creatinine ≤1.5×ULN and standardized endogenous creatinine clearance ≥60 ml/min estimated by the Cockcroft-Gault formula, Ccr(ml/min)=[(140-age)×body weight(kg)]/[72×Scr(mg/dl)], and for females, it is calculated as follows×0.85;
   5. Coagulation function: International Normalized Ratio (INR) ≤1.5;
   6. Screening period left ventricular ejection fraction (LVEF) > 50%.

10. Systolic blood pressure (SBP) < 140 mmHg and diastolic blood pressure (DBP) < 90 mmHg (no therapeutic drugs or single drug controllable).

11.1) Female: For female subjects of childbearing potential, they must have a negative serum pregnancy test within 7 days prior to enrollment and be using a medically licensed method of contraception during and for 3 months after completion of treatment; they must have a negative serum or urine pregnancy test during the Screening Period; they must not be breastfeeding; and they are considered to be of childbearing potential if they are menopausal but have not yet attained a postmenopausal status (menopausal for a period of time greater than or equal to 12 consecutive months for no reason other than no reason other than menopause) and has not undergone sterilization (removal of ovaries and/or uterus), such females are considered to be of childbearing potential. Their sexual partner is using a medically licensed method of contraception during and for 3 months after the end of the subject's treatment; 2) Males: surgical sterilization or medically licensed contraception during and for 3 months after the end of treatment; and their sexual partner is using a medically licensed method of contraception during and for 3 months after the end of the subject's treatment.

12.Ability and willingness to comply with study protocol requirements during the study and follow-up procedures.

Exclusion Criteria

1. The patient used AL8326 tablets.

2. Allergic to AL8326 or its analogues, or to any component in the prescription of AL8326;

3. The last dose of systemic cytotoxic or investigational therapy was administered within 28 days prior to initiation of study treatment. Or the last dose of a non-cytotoxic, non-investigational treatment (i.e., radiation therapy, hormone therapy, targeted therapy, immunotherapy, etc.) was administered within 14 days prior to initiation of study treatment;

4. Major surgery (defined as requiring general anesthesia within 28 days prior to initiation of study treatment or general anesthesia for minor surgical procedures within 7 days prior to initiation of study treatment).

5. Pregnant or lactating female patients.

6. History of a prior or concurrent second primary malignancy that, in the opinion of the investigator or sponsor, may interfere with the assessment of the safety or efficacy of the investigational therapeutic agents.

7. Patients with active or untreated central nervous system（CNS） metastases; subjects with stabilized brain metastases will need to meet the following criteria for enrollment: a) no imaging-proven progression ≥4 weeks after completion of treatment; b) completion of treatment within ≥28 days prior to the first dose of the test drug; and c) no need to be treated with systemic corticosteroids (>10 mg/day of prednisone or equivalent dose) ≤28 days prior to the first dose of the test drug.

8. Peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal disease with risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to starting study treatment.

9. The patients have had an arterial/venous thrombotic event such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism within 6 months prior to screening;

10. Presence of uncontrolled infection (within 2 weeks prior to administration of test drug).

11. New York Heart Association (NYHA) class III or IV congestive heart failure as achieved by cardiac function.

12. Had the following history of heart disease within 6 months before starting study treatment:

    1. Cardiac angioplasty or stenting, or
    2. Myocardial infarction, or
    3. Unstable angina, or
    4. Cerebrovascular accident

13. Imaging showed that the tumor had invaded around important blood vessels, or the investigator judged that the tumor was very likely to invade important blood vessels during the follow-up study and cause fatal massive hemorrhage;

15.With ascites or uncontrollable pleural effusion (CTCAE 5.0 ≥ grade 2). 16.Evidence of hemorrhagic idiosyncrasies or coagulation disorders or clinically significant bleeding (such as gross hematuria, gastrointestinal bleeding, and hemoptysis) detected within 6 months prior to initiation of study treatment.

17.Patients treated with anticoagulants or vitamin K antagonists (such as warfarin, heparin, or their analogues); Under the premise that the international standardized ratio of prothrombin time (INR) is ≤ 1.5, it is allowed to use low-dose anticoagulants for preventive purposes, such as warfarin (no more than 1mg per day, oral), low-dose heparin (no more than 12000 U per day), or low-dose aspirin (no more than 100mg per day); 18.There are arrhythmias that need clinical intervention (such as long QT syndrome, QTc corrected by fridericia formula is not measurable or > 450 ms in men and > 470 MS in women); 19.Within 28 days before starting the study treatment, urine protein was ≥ + +, and 24-hour urine protein quantitation was > 1.0g; 20.Hepatitis B surface antigen is positive and hepatitis B virus load (HBV-DNA) is higher than the lower limit of local laboratory detection, anti hepatitis C antibody is positive and hepatitis C virus load (HCV-RNA) is higher than the lower limit of local laboratory detection, Treponema pallidum antibody is positive, and human immunodeficiency virus anti physical examination result is positive.

21.History of organ transplantation. 22.Clinical symptoms affecting the intake or absorption of AL8326 (such as inability to swallow, chronic diarrhea, intestinal obstruction, malabsorptive disease, total gastrectomy or small bowel resection); 23.Prohibited combination drug therapy within 14 days prior to initiation of study treatment.

24.Red blood cell or platelet transfusion within 14 days prior to initiation of study treatment.

25.Any serious and/or unstable pre-existing medical, psychiatric, or other condition that may jeopardize the subject's safety, obtaining informed consent, or compliance with study procedures or study objectives.

26.Any other reason that, in the judgment of the investigator, makes participation in this study inappropriate.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
AL8326	AL8326 tablets	Subject will received AL8326 once daily for 28-days cycle until intolerable toxicity or disease progression or death or voluntary withdrawal the end of this study. Subjects will be evaluated for anti-tumor efficacy and corresponding safety examinations every 2 cycles, and tumor disease status will be according to Response Evaluation Criteria in Solid Tumours（RECIST 1.1）.

Primary Outcome Measures

Name	Time	Method
Objective remission rate (ORR)	Every 2 cycles,up to 24 months (each cycle is 28 days)	The proportion of subjects achieving complete remission (CR) and partial remission (PR) with optimal efficacy according to RECIST 1.1.

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival (PFS)	Every 2 cycles,up to 24 months (each cycle is 28 days)	The period of time between the start of the subject's first dose of medication and the first observation of disease progression (based on imaging) or the occurrence of death due to any cause.
Overall Survival (OS)	Cycle 1 Day 1 up to 24 months(each cycle is 28 days)	Defined as the time between the date of first dose and death from any cause. Subjects who are alive as of the date of analysis will use and the date they last achieved survival as the cutoff time.
Plasma Concentration	Cycle 1 Day 1，Cycle 1 Day14，Cycle 1 Day 28 (each cycle is 28 days)	PK samples of some subjects treated with study drugs will be collected for pharmacokinetic analysis in this study.
Duration of remission (DOR)	Every 2 cycles,up to 24 months (each cycle is 28 days)	The time between the start of the first assessment of the tumor as CR or PR and The first assessment of disease progression (PD) or death from any cause.
Disease Control Rate (DCR)	Every 2 cycles,up to 24 months (each cycle is 28 days)	The proportion of subjects achieving complete remission (CR), partial remission (PR) and stable disease (SD).
Duration of Disease Control (DDC)	Every 2 cycles,up to 24 months (each cycle is 28 days)	The time from the first assessment of the tumor as CR, PR, or SD to the first assessment of disease progression (PD) or death from any cause.

Trial Locations

Locations (10)

The First Affiliated Hospital of Bengbu Medicaal University; 🇨🇳 Bengbu, Anhui, China

Anhui Provincial Cancer Hospital; 🇨🇳 Hefei, Anhui, China

Xuancheng People´s Hospital; 🇨🇳 Xuancheng, Anhui, China

Anyang Cancer Hospital; 🇨🇳 Anyang, Henan, China

Henan Cancer Hospital; 🇨🇳 Zhengzhou, Henan, China

Sir Run Run Shaw Hospital (SRRSH),affiliated with Zhejiang University School of Medicine; 🇨🇳 Hangzhou, Zhejiang, China

The First Affiliated Hospital of Zhengzhou University; 🇨🇳 Zhengzhou, Henan, China

Hubei Cancer Hospital; 🇨🇳 Wuhan, Hubei, China

Nanjing Chest Hospital; 🇨🇳 Nanjing, Jiangsu, China

The First Hospital Of Jiaxing; 🇨🇳 Jiaxing, Zhejiang, China